With respect to the Canadian HIV Vaccine Initiative (CHVI) and the Level 5 Laboratory (L5L): (a) what are the details of the initial request for proposals for the CHVI; (b) what amount were the government and the Gates Foundation planning to invest in the CHVI and what were the scheduled dates for investment; (c) how many bids for the CHVI were submitted and by which organizations; (d) what are the details of the CHVI process for determining suitable award winners; (e) what were the selection criteria for awarding the CHVI bid and who was responsible for identifying the criteria; (f) how many people made up the independent evaluation committee for the CHVI bids, how were they selected, and from which disciplines and geographic areas were they drawn; (g) were representatives from the pharmaceutical industry invited to be part of the independent evaluation committee for the CHVI bids and, if so, on what date did each representative serve and, if not, why not; (h) what were the results for each of the selection criterion for each of the organizations bidding on the CHVI and how were the bids ranked; (i) did the independent evaluation committee for the CHVI bids reach a recommendation, and, if so, on what date, and to whom was the information conveyed in the government; (j) was there a steering committee for the CHVI bids and, if so, who were the members, who was the chair and what was its mandate; (k) were there changes to the steering committee for the CHVI bids and, if so, on what dates and for what reasons; (l) was any organization bidding on the CHVI informed, formally or otherwise, that it had been chosen to host the facility and, if so, how and on what date; (m) did the federal government put up a notice on its Web site to announce that the CHVI project had been cancelled or would not proceed and, if so, on what date; (n) was the notice in (m) removed from the Web site and, if so, on what date and for what reason; (o) have each of the organizations bidding on the CHVI seen the results of the peer-review process and, if so, on what date and, if not, why not; (p) what constructive criticism was given to each of the organizations bidding on the CHVI; (q) what specific problems were identified that prevented each of the organizations bidding on the CHVI from being selected; (r) why were bidding organizations not encouraged to redevelop their CHVI bid; (s) why and by whom was the CHVI cancelled; (t) on what dates was the CHVI project cancelled, were the submitting organizations formally informed and was the Canadian public informed; (u) what do “changing needs” and “reallocation of resources” mean in relation to the cancellation of the CHVI project; (v) what post-mortem audit does the government plan to undertake to investigate how Canadian investigators and research centres failed to meet the selection criteria for the CHVI bid; (w) how will the planned CHVI investment monies be spent; (x) what are the details of both the CHVI’s and the L5L’s history from January 2009; (y) what are the organizations involved in the L5L, and what, if any, overlap (e.g., goals, funds, personnel, etc.) exists between the International Centre for Infectious Diseases, who was bidding for the CHVI, and the L5L; (z) what, if any, involvement does the government have in the L5L; and (aa) what, if any, review process is in place for the L5L?
In the House of Commons on April 16th, 2010. See this statement in context.